{"id":"diquafosol-ophthalmic-sodium-solution-3","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Eye irritation"},{"rate":null,"effect":"Ocular discomfort"},{"rate":null,"effect":"Taste perversion"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Diquafosol sodium activates P2Y2 receptors on the ocular surface, triggering increased mucin secretion from goblet cells and aqueous tear secretion from lacrimal glands. This mechanism addresses the underlying pathophysiology of dry eye disease by promoting endogenous tear production rather than simply lubricating the eye surface.","oneSentence":"Diquafosol is a P2Y2 purinergic receptor agonist that stimulates secretion of mucin and aqueous fluid from conjunctival and lacrimal glands to increase tear production.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:09:36.104Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dry eye disease (keratoconjunctivitis sicca)"}]},"trialDetails":[{"nctId":"NCT06903884","phase":"PHASE3","title":"3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis","status":"NOT_YET_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2025-12-30","conditions":"Vernal Keratoconjunctivitis","enrollment":94},{"nctId":"NCT07122635","phase":"","title":"Effectiveness of Dry Eye Treatment With Diquafosol Sodium 3% After Phaco Surgery","status":"COMPLETED","sponsor":"Le Xuan Cung","startDate":"2024-10-03","conditions":"Dry Eye Disease","enrollment":60},{"nctId":"NCT05682547","phase":"NA","title":"Diquafosol vs Hyaluronic Acid for Diabetic Dry Eye","status":"COMPLETED","sponsor":"He Eye Hospital","startDate":"2022-12-01","conditions":"Diabetic Eye Problems","enrollment":99},{"nctId":"NCT06427031","phase":"PHASE3","title":"Comparing Efficacy and Safety of TJO-083 in Dry Eye Diseases Patients","status":"COMPLETED","sponsor":"Taejoon Pharmaceutical Co., Ltd.","startDate":"2023-07-14","conditions":"Dry Eye, Dry Eye Syndromes","enrollment":271},{"nctId":"NCT05383612","phase":"NA","title":"To Evaluate the Efficacy of Diquafosol Sodium in the Treatment of MGD in Different Treatment Pattern","status":"UNKNOWN","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2022-08-05","conditions":"Dry Eye, Meibomian Gland Dysfunction","enrollment":140},{"nctId":"NCT04980144","phase":"NA","title":"Diquafosol Ophthalmic Solution for Dry Eye Symptoms","status":"UNKNOWN","sponsor":"He Eye Hospital","startDate":"2023-03-03","conditions":"Diabetic Eye Problems","enrollment":101},{"nctId":"NCT04668118","phase":"PHASE4","title":"The Effect of 3% Diquafosol Ophthalmic Solution on Visual Display Terminal-associated Dry Eye","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2021-02-01","conditions":"Dry Eye Syndromes, Computer Vision Syndrome, Asthenopia","enrollment":68},{"nctId":"NCT05346783","phase":"PHASE1, PHASE2","title":"Comparing Efficacy and Safety of TJO-083 in Dry Eye Disease Patients","status":"UNKNOWN","sponsor":"Taejoon Pharmaceutical Co., Ltd.","startDate":"2021-10-14","conditions":"Dry Eye Syndromes","enrollment":98},{"nctId":"NCT03640351","phase":"NA","title":"Clinical Effects of Diquas-S for Patients With Dry Eye After Cataract Surgery","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2017-08-15","conditions":"Dry Eye, Cataract Surgery","enrollment":150},{"nctId":"NCT02608489","phase":"NA","title":"Clinical Effects and Safety of 3% Diquafosol After Cataract Surgery","status":"COMPLETED","sponsor":"Soonchunhyang University Hospital","startDate":"2014-01","conditions":"Dry Eye Syndromes","enrollment":86}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Diquafosol ophthalmic sodium solution 3%","genericName":"Diquafosol ophthalmic sodium solution 3%","companyName":"Taejoon Pharmaceutical Co., Ltd.","companyId":"taejoon-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Diquafosol is a P2Y2 purinergic receptor agonist that stimulates secretion of mucin and aqueous fluid from conjunctival and lacrimal glands to increase tear production. Used for Dry eye disease (keratoconjunctivitis sicca).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}